Antibacterial oral sprays from kaffir lime (Citrus hystrix DC.) fruit peel oil and leaf oil and their activities against respiratory tract pathogens

Background and aim

Kaffir lime fruit peel oil and Kaffir lime leaf oil have been reported for their activities against respiratory tract pathogens. The purpose of the study was to develop clear oral sprays to be used as a first-defense oral spray.

Experimental procedure

Clear antibacterial oral sprays were prepared and analyzed for their respective active major compounds, using GC-MS. The sprays were tested against a Gr. A streptococcal clinical isolate and 3 standard respiratory tract pathogens, using Broth microdilution method. A 4-month stability test was carried out as well.

Results and conclusion

Six clear oral sprays, three formulae composed of Kaffir lime fruit peel oil (6, 10, 13%v/v KLO) and the other three formulae containing Kaffir lime leaf oil (4, 8, 12%v/v KLLO), were developed. The active compounds in KLO were α-terpineol and terpinene-4-ol whereas that in KLLO was citronellal. All oral sprays exhibited antibacterial activity against one Group A streptococcal clinical isolate and three respiratory pathogenic pathogens, Staphylococcus aureus ATCC 29213, Streptococcus pneumoniae ATCC 49619, and Haemophilus influenzae ATCC 49247, among which the strongest activity was against H. influenzae ATCC 49247. The antibacterial activity of all oral sprays remained unchanged in an accelerated stability test, at 4, 30, and 45 °C under 75% relative humidity, throughout the 4-month storage.

•

Clear antibacterial oral sprays were prepared.

•

Active major compounds were alpha-terpineol, terpinene-4-ol, and citronellal.

•

The sprays showed strongest activities against Haemophilus influenzae ATCC 49247.

•

The antibacterial activity was shown throughout 4-month storage.

Genetic variation in wild and hatchery populations of giant freshwater prawn (Macrobrachium rosenbergii) revealed by randomly amplified polymorphic DNA markers

Sustainable improvement and conservation of any genetic resource depend on the assessment of its intra- and inter-population genetic variation. In order to estimate genetic variation in both wild and hatchery populations of Macrobrachium rosenbergii, randomly amplified polymorphic DNA (RAPD) analysis was performed. Analyses of 51 polymorphic loci amplified from genomic DNA by three decamer random primers revealed different degrees of genetic variation in two wild (Bhairab and Rupsha rivers) and hatchery-derived gher (Gher-1 and Gher-2) populations. The proportion of polymorphic loci was found to be higher in wild populations (0.90 and 0.65 for the Bhairab and Rupsha populations, respectively) than the hatchery-derived gher populations (0.29 and 0.16 for Gher-1 and Gher-2, respectively). Likewise, the river populations contained higher levels of gene diversity (0.221 and 0.179 for Bhairab and Rupsha populations, respectively) than the gher populations (0.114 and 0.045 for Gher-1 and Gher-2, respectively). These results suggest reduction of genetic variation and heterozygosity in the hatchery-derived gher populations. Inter-population similarity indices and pairwise genetic distance values showed that variation between the wild or between the gher populations were lower than those between the wild and hatchery populations. On average, 14 loci exhibited significant deviation from homogeneity in wild vs hatchery population pairs, whereas 2 and 3 loci showed heterogeneity in Gher-1 vs Gher-2 and Bhairab vs Rupsha population pairs, respectively. A genetic distance-based UPGMA dendrogram segregated river populations from the gher populations. Our study, therefore, revealed substantial levels of genetic variation between wild and hatchery populations of M. rosenbergii.

Molecular techniques for the personalised management of patients with chronic myeloid leukaemia

Chronic myeloid leukemia (CML) is the paradigm for targeted cancer therapy. RT-qPCR is the gold standard for monitoring response to tyrosine kinase-inhibitor (TKI) therapy based on the reduction of blood or bone marrow BCR-ABL1. Some patients with CML and very low or undetectable levels of BCR-ABL1 transcripts can stop TKI-therapy without CML recurrence. However, about 60 percent of patients discontinuing TKI-therapy have rapid leukaemia recurrence. This has increased the need for more sensitive and specific techniques to measure residual CML cells. The clinical challenge is to determine when it is safe to stop TKI-therapy. In this review we describe and critically evaluate the current state of CML clinical management, different technologies used to monitor measurable residual disease (MRD) focus on comparingRT-qPCR and new methods entering clinical practice. We discuss advantages and disadvantages of new methods.

A pragmatic approach to the analysis of a combination formulation

The aim of the paper was to formulate a combined oral dosage form of rosuvastatin calcium and amlodipine besylate and to develop and validate an analytical method to be adopted for both routine quality control assay and in vitro dissolution studies of the formulation.

The proposed combination formulation has shown compatibility with the chosen excipients, verified through FT-IR study. A novel gradient RP-HPLC method was developed and validated according to the ICH guideline which was found to be suitable for the simultaneous estimation of rosuvastatin calcium and amlodipine besylate from the formulation. The retention time of 2.7 and 6.08 min allows the analysis of large amount of samples with less mobile phase which makes the method economic. The dissolution profiles of both the drugs in different dissolution medium were encouraging which makes the combination formulation of rosuvastatin calcium and amlodipine besylate superior and effective in achieving patient compliance.